Capturing the angel in angel dust: Twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans

Schizophrenia Bulletin

Volumn 38, Issue 5, 2012, Pages 942-949

  Moghaddam, Bita ^a   Krystal, John H ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

glutamate; ketamine; NMDA

Indexed keywords

AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; DIZOCILPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; EGLUMETAD; GLUTAMIC ACID; KETAMINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; PLACEBO;

ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; COGNITION; DRUG EFFECT; DRUG TARGETING; HUMAN; NEUROIMAGING; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; SYNAPSE; TRANSLATIONAL RESEARCH;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOPAMINE; EMOTIONS; GLUTAMIC ACID; HUMANS; KETAMINE; NEUROSCIENCES; PHENCYCLIDINE; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, DOPAMINE D2; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPSES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84866652398     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbs075     Document Type: Article

References (50)

1. Luby E, Cohen B, Rosenbaum G, Gottlieb J, Kelley R. Study of a new schizophrenomimetic drug-sernyl. AMA Arch Neurol Psychiatry. 1959;81:363-369.
2. Bowers MB Jr, Hoffman FJ Jr. Homovanillic acid in rat caudate and prefrontal cortex following phencyclidine and amphetamine. Psychopharmacology. 1984;84:136-137.
3. Freeman AS, Bunney BS. The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur J Pharmacol. 1984;104:287-293.
4. Carlsson A, Hansson LO, Waters N, Carlsson ML. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci. 1997; 61:75-94.
5. Coyle J. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 1996;3:241-253.
6. Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry. 1987;9:12-35.
7. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurosci. 1990;54:1755-1760.
8. Carlsson M, Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monamine-depleted mice. J Neural Transm. 1989;75:221-226.
9. Adams B, Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci. 1998;18:5545-5554.
10. Heninger GR, Charney DS, Sternberg DE. Serotonergic function in depression. Prolactin response to intravenous tryptophan in depressed patients and healthy subjects. Arch Gen Psychiatry. 1984;41:398-402.
11. Aghajanian GK. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature. 1978;276:186-188.
12. Kupfer A, Schmid B, Preisig R, Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet. 1984;2:517-518.
13. Krystal JH, D'Souza DC, Petrakis IL, et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry. 1999;7:125-143.
14. Ghoneim M, Hinrichs J, Mewaldt S, Petersen R. Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol. 1985;5:70-77.
15. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
16. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996;14:301-307.
17. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)-and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7:25-38.
18. Liu J, Moghaddam B. Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J Pharmacol Exp Therap. 1995;274:1209-1215.
19. Verma A, Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci. 1996;16:373-379.
20. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921-2927.
21. Moghaddam B, Adams B. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281:1349-1352.
22. Schoepp DD, Johnson BG, Wright RA, et al. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology. 1997;36:1-11.
23. Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Therap. 1999;291: 161-170.
24. Jackson M, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA. 2004;101:8467-8472.
25. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007;27:11496-500.
26. Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol. 2006;63:1372-1376.
27. Buchanan RW, Keefe RS, Lieberman JA, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. 2011;69:442-449.
28. Krystal JH, Karper LP, Bennett A, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology. 1998;135:213-229.
29. Lipschitz D, D'Souza DC, White JA, Charney D, Krystal J. Clozapine blockade of ketamine effects in healthy subjects. Biol Psychiatry. 1997;41(suppl):23S.
30. Krystal JH, D'Souza DC, Karper LP, et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology. 1999;145:193-204.
31. Krystal JH, Perry EB Jr, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005;62:985-994.
32. Krystal JH, D'Souza DC. Comment on "Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D(2) receptor." Biol Psychiatry. 2001;50:555-556.
33. Gattaz WF, Schummer B, Behrens S. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm Gen Sect. 1994;96:227-232.
34. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57:270-276.
35. Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol. 2007;27:582-589.
36. Krystal JH, Abi-Saab W, Perry E, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl). 2005;179:303-309.
37. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102-1107.
38. D'Souza DC, Singh N, Elander J, et al. Glycine transporter inhibition attenuates the psychotomimetic effects of ketamine in healthy humans subjects. Neuropsychopharmacology. 2012;37:1036-1046.
39. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron. 2003;40:881-884.
40. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003;169:215-233.
41. Homayoun H, Jackson ME, Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol. 2005;93:1989-2001.
42. Kinon BJ, Zhang L, Millen BA, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31:349-355.
43. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol. 2010;77:317-326.
44. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl). 2004;174:39-44.
45. Kinney G, Burno M, Campbell U, et al. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Therap. 2003;306:116-123.
46. Tost H, Meyer-Lindenberg A. Dopamine-glutamate interactions: a neural convergence mechanism of common schizophrenia risk variants. Biol Psychiatry. 2011;69:912-913.
47. Gordon JA. Testing the glutamate hypothesis of schizophrenia. Nature Neurosci. 2010;13:2-4.
48. Xu B, Roos JL, Dexheimer P, et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet. 2011;43:864-868.
49. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry. 1998;43:811-816.
50. Stone JM, Dietrich C, Edden R, et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry. 2012.